Company: BUDZ
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001096906-25-000350
Chunk: 94

Company: WEED, INC.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 94
---
 and “accredited investors” must make a special written determination that the
penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. Consequently,
these requirements may have the effect of reducing the level of trading activity, if any, in the secondary market for a security subject
to the penny stock rules, and investors in our common stock may find it difficult to sell their shares.

17

ITEM 1B – UNRESOLVED STAFF COMMENTS

This Item is not applicable
to us as we are not an accelerated filer, a large accelerated filer, or a well-seasoned issuer; however, we have not received written
comments from the Commission staff regarding our periodic or current reports under the Securities Exchange Act of 1934 within the last
180 days before the end of our last fiscal year.

ITEM 1C – CYBERSECURITY

The identification, detection,
prevention and remediation of known or potential IT security vulnerabilities, including those arising from third-party hackers, hardware
or software, is extremely costly and time consuming. Company does not have the manpower, expertise or financial resources to effectively
identify, detect, prevent or remediate cybersecurity risks. No assurance or guarantee whatsoever can be given that Company will not be
damaged by the exploitation of its cybersecurity vulnerabilities.

During the year ended, we
did not identify any cybersecurity threats that have materially affected or are reasonably likely to materially affect our business strategy,
results of operations, or financial condition. However, we may not be aware of all vulnerabilities or might not accurately assess the
risks of incidents, and such preventative measures cannot provide absolute security and may not be sufficient in all circumstances or
mitigate all potential risks.

ITEM 2 – PROPERTIES

Le Veta, Colorado Properties

On July 26, 2017, we acquired
a property located in La Veta, Colorado in order for Sangre to complete its 5-Year, $15+ million Cannabis Genomic Study. The site includes
a 10,000+ sq. ft. building that will house Sangre’s genomic research facility, a 4,000+ square foot building for plant product analytics
and plant product extraction, a 3,500 sq. ft. corporate office center, and 25 RV slots with full water and electric, which we plan to
convert into a series of small research pods. Under the terms of the purchase agreement, we paid $525,000 down, along with 25,000